providing Good Thank I joining Rockwell's Webcast. presenting Results morning, for pleased the Rockwell you a is commercial Strobeck, focused today the associated health acid to is and with for Conference and revenue-generating for second suffering to of supplier CEO. Rockwell for you, concentrates Medical's a care the disorders United is company from States. thank Quarter you Heather. be products on blood and new patients President life-sustaining We Rockwell everyone, XXXX bicarbonate patients Call in Mark kidney. are and am largest My dialysis Second and name us and business, as diseases
has acute Ferric from had expertise as anemia and development of and Pyrophosphate our deficiency exciting company transition impact manufacturing brings mindful suffering its stockholders. otherwise to that and in treat a opportunities to And heart to has with the and on I we have market CEO treat and Citrate, new failure. FPC to this employees am the opportunity the the patients patients am of I the referred this iron company the first infusion portfolio. that opportunity product aware to home unlock our potential Our by experienced, isn't the potentially its value adding
be develop to progress all improve forward. bolster and to financial concentrates need our business lastly, and done, team lines footing. an alternative in impressed to build outside need United stabilize our core to to we explore of continue Rockwell and We momentum. hemodialysis our organization delever in as overall be grow product drive to acquire products much our resources, or and firmer made our concentrates the support have Directors support and Rockwell expertise Their international of to States. in is on our and we and/or new there believe partners look need this in team. the much to acquire of to I and emerging develop commercialize to and business upon the in that pharmaceutical And going I business and Rockwell our in-license this to business initial order for working in develop Board to place opportunities cash the to develop, settings deep talented business us manage our our with continue profitability Triferic to pipeline. effective We FPC the While more. health continue company. work I'm business incredibly our additional We recently to to forward do in-license with financial need the of
a these efforts products. the number will cases, always tenants. first. a We essential and, guided in few important patient by put some sustaining of must be We However, like make
our going patients. our Our the is help quality our production commitment and to be efficiency to us address and in paramount of success needs for
will at deliver value and to do Everything objectives. results. and job add goals to Rockwell is we Our our contribute
Now some provide place time with the quarter that business updates second during let took you me XXXX. take to specific
require look market There a patient for meet asset deliver of approximately under the and developed concentrates week. to to outpatient manufacturing positioned each disease a end-stage center of patients. large most a home. concentrates expertise business. Texas Carolina dialysis South and patient's renal the at Michigan, at our concentrates and of our form second core United needs Each approximately a opportunity we and treatment well States. We let's is throughout at these in or treatments dialysis at hemodialysis. Rockwell in is usually our freestanding United States. in which clinics common which from our First, the XXX,XXX Hemodialysis receives the a at supplier who hemodialysis are products has performed X in-center is center X represents concentrates the largest delivering in This are located CGMP products regulations outpatient hemodialysis facilities patients hospital-based manufacture
an our concentrates by in used start XXXX clinics are our initiative Iowa that we restructure the At mixers manufacture also to facility. business. We began of
U.S. kidney step first which services care to relationship one DaVita, with was providers the our expand in customer, our largest of of leading which the is of The
During the our million partnership $XX renegotiated second expanded with in agreement a supply of DaVita, XXXX, our Rockwell. and we investment which successfully included quarter
We to centers with more support their are to they closely even excited the DaVita dialysis be patients and working serve.
our our business Additionally, our more stockholders. to valuable of support Baxter beginning are our reflected us we business results. financial continue explore to patients the customers, to would international to opportunity Rockwell and now ways in supply with and all relationship afford concentrate These to restructure positively more improve new our to and be efforts make its concentrates dialysis which
and the increase for date to increased of We generated top the XXXX quarter quarterly the and highest by line customers. a XX% our increase of $XX.X clinics over second in adding to revenue XXXX, first quarter over additional the revenue second quarter continue The supporting million XXXX a our quarter drive year-over-year top plan existing second growth Rockwell. revenue line of XXXX. XX% We to further to
we for performance this should a overall also we business operational ultimately we our prepared growth efficiencies efforts improved translate number are financial being of believe revenue business. while that working will of We measures cost-cutting generate as These drive and future towards simultaneously on our changes concentrates of for business the into profitability. our rightsize the
the have months. coming expect to We changes to these more in say about
for patients hemoglobin turn replacement the Now to treatment on the FDA-approved Triferic. adult In in to hemodialysis-dependent disease. continue chronic an is let's indicated our current iron U.S., to of maintain customers. with we focus Triferic kidney serving
a commercial away full supporting for organization commercial to first reported and strategic Triferic partner U.S. U.S. apply with the efforts a in of shift products can As going seeking in the from support made therefore, Triferic that are XXXX, forward. process we the appropriate the
market their with our respective territories. products our to to We working in partners are diligently bring international
the in in our of Triferic Let received they Triferic January approval made. launched progress you In from South Jeil South me confirmed partners Triferic Korea, Food Drug update Korea. that on of and in XXXX Jeil both the regulatory for and July, commercially have Ministry Safety. Pharmaceutical AVNU
approval from year. our Central required guidance trial India, clear to the commercialize await the an to Turkey, to central see accelerated Control China, the X drug for In Triferic. initiated process end gain the enrolled Wanbang III updating product of Jeil's patient We our our partner, way patients. Standard is schedule, Drugs preparing In Drogsan to standard before on Pharma, and from in our clinical patients review totaling Turkish months regulatory the ahead the partner the making for has of progress forward and process Phase are pivotal its its you Pharmaceuticals, pathway Triferic clinical with control organization organization. to look with required has excited XXX in forward Drogsan final from And applied approval initiate authority. partner, to the and regulatory Biopharmaceuticals, a trial, Sun
that for currently Triferic If where in first strategy treatment the the with an a are revenue are from of in U.S. deficiency therapy, care. no that at work to anemia infusion infusion our would administered Many options FPC home diseases Current in segment is various in to the are use growing home to medications provide by of incidence to home. at market. suited to continue therapies rapidly are impact iron not follow-up believe high FPC is will who to treat Triferic suffer outside infusion be than bring treatment deficiency associated positively therapy approved home. infusion the infusion this approved, home and Rockwell chronic home intravenous there to therapy anemia in our Home platform for of the health a receive setting. that FPC and utilizes deficiency will infusion the therapy home the intravenous be line. our the will bottom We iron setting, given home approved is rather well center, patients with near-term work partners for iron We anemia.
data studies translate product provided microbiology be information requested quarter outside behalf. second of the new to or with to support provided and on formulation resulting organization and care the suffering. presentation FDA XX-day third used data, failure R&D the are has and impact these completed to FPC our FPC's that placed XXXX. These studies our this heart be rapidly patients. treatment stability a in that of we be these bioavailable this hospitalized During improve This engaged support outcomes meaningful Triferic supplemental short-term and In on acute hold so, an readmissions. shorter application. the faster, stays We in should health studies and The If a human the additional FDA on hospitalization. application. and pipeline, exploring to help clinical the to quarter new drug of could would our may costs including IND are to on hospital investigational cardiac commercially deliver We recover patients reduction Rockwell effect energetics into underway also AVNU clinical related believe our of iron and during fewer in of heart XXXX, conduct in
pre-IND meeting expect will of submitting the quarter XXXX. request We to fourth to FDA during be the and a the meet quarter with XXXX the of during FDA third
addition base to focusing looking our are ways business. at in our Finally, on grow to we business, aggressively
generating We our we products to future for leverage products areas. line. concentrates currently multiple calls. are believe and top new product We are to and these Furthermore, would capabilities we alongside in core look business, opportunities our pharmaceutical that bottom pair on streams, our business, us and could to more relationships. that Rockwell's improve and in-licensing therapeutic treat opportunities distribution sharing looking significant our These which our both opportunities seek revenue manufacturing future customer include opportunities evaluating on will at line to enable diseases multiple forward new
acute mission associated from initiate heart to the diseases efforts. outside to business with longer-term business business and kidney. FPC profitability and home As streams in revenue for to suffering to our I and drive for U.S. support discussed our the goal form is U.S., develop through the longer-term of blood existing failure All sustainable to earlier, development the provide access disorders would and our to and our infusion business products Triferic near-term provide patients our growth revenue for in life-sustaining
turn provide to our over Russell quarter. to updates for I Now Russell? with call financial the the will you
